The following CONARIS product candidates have reached application in humans:



OlamkiceptDrug candidate: IL-6 trans-signalling inhibitor (out-licensed to Ferring Pharmaceuticals)
CR12/01Drug candidate: gut microbiota modulator (small molecule)
CR12/02Drug candidate: gut microbiota modulator (small molecule)
CR13/01Drug candidate: intestinal microenvironment transfer / fecal filtrate transfer (sold in 2017)
CR19/01-04Gut microbiome-modulating dietary supplements (out-licensed in 2020)

24 February, 2021